WC
William Carson
Chief Medical Officer, Otsuka Pharmaceutical Development & Commercialization
Otsuka HoldingsTherapeutic Areas
Otsuka Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Abilify (aripiprazole) | Schizophrenia, Bipolar Disorder | Commercial |
| Rexulti (brexpiprazole) | Major Depressive Disorder, Schizophrenia | Commercial |
| Abilify Maintena | Schizophrenia, Bipolar I Disorder | Commercial |
| OPC-64005 | Alzheimer's Disease Psychosis | Phase 3 |
| Centanafadine | ADHD | Phase 3 |
| OPC-34712 | Major Depressive Disorder | Phase 2 |
| Nuedexta (AVP-923) | Pseudobulbar Affect | Commercial |
| Jynarque/Jinarc (tolvaptan) | ADPKD | Commercial |